Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial

BMC Musculoskeletal Disorders

Marcee Maroney¹  Dawn P Gill⁶  Frank Dellaert²  Julia Alleyne⁴  Pieter J Emans⁵  Robert J Petrella³ 

[1] Carbylan Therapeutics, Palo Alto, USA;Care to Move, St. Niklaas, Belgium;Aging, Rehabilitation & Geriatric Care Research Centre, Lawson Health Research Institute & Departments of Family Medicine, Kinesiology and Cardiology, Western University, London, Canada;Department of Family and Community Medicine, University of Toronto & Sport CARE, Women’s College Hospital, Toronto, Canada;Department of Orthopaedic Surgery, Maastricht University Medical Center, Maastricht, the Netherlands;Department of Epidemiology, University of Washington, Seattle, USA

关键词: Viscosupplementation;    Triamcinolone acetonide;    Hyaluronic acid;    Knee Osteoarthritis;   

Others  :  1139080
DOI  :  10.1186/s12891-015-0513-6

 received in 2014-10-07, accepted in 2015-02-27,  发布年份 2015

【 摘 要 】

Background

Studies have evaluated the concomitant use of hyaluronan (HA) with steroids, anti-inflammatory drugs and analgesic agents in an attempt to magnify the extent and duration of pain relief due to knee osteoarthritis. To date there has not been an intra-articular combination therapy available for relief of knee osteoarthritis symptoms – one that combines the fast acting onset of symptom relief provided by a corticosteroid with the long-lasting symptom relief provided by HA in a single injection. The objective of this study was to evaluate the safety and preliminary performance of two new HA formulations, Hydros (hyaluronan-based hydrogel suspended in hyaluronan solution) and Hydros-TA (HA plus 10 mg of triamcinolone acetonide [TA]) in subjects with knee osteoarthritis.

Methods

We conducted a Phase 2 prospective, multicenter, randomized, double-blind feasibility trial. Participants (n = 98; mean age 60 years) with knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) were randomized to three treatment groups: Hydros, Hydros-TA, and Synvisc-One® (hylan G-F 20). Participants received one 6 ml intra-articular injection in the treatment knee and were evaluated at 2, 6, 13, and 26 weeks post-treatment. Safety was assessed from adverse events at all study visits. The primary efficacy outcome was the change from baseline on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A (Pain) score for the treatment knee.

Results

Adverse events were similar across treatment groups with the most common being arthralgia, joint swelling, back pain, and joint stiffness. Arthralgia was reported 5 times with Synvisc-One, 4 with Hydros, and 1 with Hydros-TA. Each group demonstrated a reduction in the WOMAC A (Pain) score over 26 weeks: [least-square mean (standard error)] 30.5 (5.1) mm for Hydros; 34.4 (4.7) mm for Hydros-TA; 28.0 (5.4) mm for Synvisc-One and an observed improvement of 2.5 mm (p = 0.64) and 6.4 mm (p = 0.24) over Synvisc-One for Hydros and Hydros-TA, respectively.

Conclusions

A single injection of Hydros or Hydros-TA was well-tolerated and relieved pain associated with knee osteoarthritis over 26 weeks. Data indicate that Hydros-TA had a more rapid pain relief compared to Hydros alone. A Phase 3 trial is underway to confirm these preliminary results.

Trial registration number

NCT01134406.

【 授权许可】

   
2015 Petrella et al.; licensee BioMed Central .

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Gerwin N, Hops C, Lucke A: Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 2006, 58:226-42.
• [2]World Health Organization: The global burden of disease: 2004 update In Department of health statistics and informatics in the information. Evidence and Research Cluster of WHO, Geneva; 2008.
• [3]Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al.: OARSI recommendations for the management of hip and kneeosteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000.
• [4]Schante C, Zuber G, Herlin C, Vandamme T: Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr Polym 2011, 85:469-89.
• [5]Miyakoshi N, Kobayashi M, Nozaka K, Okada K, Shimada Y, Itoi E: Effects of intraarticular administration of basic fobroblast growth factor with hyaluronic acid on osteochondral defects of the knee in rabbits. Arch Orthop Trauma Surg 2005, 125(10):683-92.
• [6]Ghosh P, Read R, Numata Y, Smith S, Armstrong S, Wilson D: The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep: II. Cartilage composition and proteoglycan metabolism. Semin Arthritis Rheum 1993, 22(6 Suppl 1):31-42.
• [7]Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE: Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis – meta-analysis. Osteoarthritis Cartilage 2011, 19(6):611-9.
• [8]Bellamy N, Campbell J, Welch V, Gee TL, Bourne R, Wells GA: Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, 2:CD005321.
• [9]Creamer P: Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how? Ann Rheum Dis 1997, 56:634-6.
• [10]Arroll B, Goodyear-Smith F: Corticosteroid injections for osteoarthritis of the knee: meta-analysis. Br Med J 2004, 328:869.
• [11]Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al.: Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003, 48:370-7.
• [12]Bellamy N, Campbell J, Welch V, Gee TL, Bourne R, Wells GA: Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, 2:CD005328.
• [13]Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE: Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteorarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009, 61(12):1704-11.
• [14]Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R: The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. Rheumatol Int 2006, 26:314-9.
• [15]Ayral X: Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2001, 15:609-26.
• [16]Grecomoro G, Piccione F, Letizia G: Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open study. Curr Med Res Opin 1992, 13:49-55.
• [17]Kellgren JH, Lawrence JS: Radiographic assessment of osteo-arthritis. Ann Rheum Dis 1957, 16(4):494-502.
• [18]Bellamy N. WOMAC® Osteoarthritis Index. User Guide IX 2009.
• [19]Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al.: OMERACT-OARSI initiative: osteoarthritis research society international set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004, 12(5):389-99.